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Key points for decision makers 
• A high level of redaction features in current NICE STA guidance – both for academic 
and commercial reasons, which also may be increasing over time 
• The level of redaction present is variable between STAs – in many cases leading to 
decisions which do not appear justified, and in others inadvertently revealing 
supposedly confidential discounts  
• An improvement is needed to the status quo to ensure appropriate redaction is 
applied so as not to undermine the transparency of health technology appraisal 
Abstract 
Introduction 
Health technology assessment (HTA) aims to provide a transparent framework within which 
normative judgements can be applied for decision making. Such transparency enables the 
public to understand the rationale for decision-making rationale but conflicts with companies 
being able to offer commercially-sensitive discounts. We investigated how to balance these 
conflicting ideals. 
Methods 
National Institute for Health and Care Excellence (NICE) submissions were reviewed for 
products with an approved, simple Patient Access Scheme (PAS) discount. The approach to 
censoring was noted (e.g. total cost and clinical outcomes redacted). Submissions were then 
assessed for transparency (i.e. whether the decision appeared justifiable given the available 
information), and confidentiality (i.e. whether the PAS discount could be ‘back calculated’).  
Results 
118 products have an approved commercial arrangement, of which 110 have simple PAS 
discounts considered within the NICE Single Technology Assessment programme. A 
definitive incremental cost-effectiveness ratio was presented within final NICE guidance in 
only 20 appraisals. Documentation for seven appraisals allowed for the straightforward ‘back 
calculation’ of PAS discounts. Furthermore, a large amount of information was censored as 
academic-in-confidence and remains so many years later.  
Discussion 
Appropriate redaction ensures discounts remain confidential, yet maintains the transparency 
of HTA decisions made. Complete redaction does not allow for transparent, justifiable 
decision making. However, redacting ‘enough’ information to preclude direct estimation of 
discounts provides a means of maintaining both transparency and confidentiality. This study 




1. Introduction  
When health technology assessment (HTA) agencies such as the National Institute for 
Health and Care Excellence (NICE) assess the cost-effectiveness of new interventions, the 
incremental cost-effectiveness ratio (ICER, or cost per quality-adjusted life year [QALY] 
gained) plays a pivotal role. For interventions associated with an ICER greater than the 
willingness-to-pay threshold (λ) specified by NICE, it is unlikely that NICE would issue a 
positive recommendation. This is because an ICER higher than λ implies a displacement of 
treatments or services within the National Health Service (NHS) that offer equivalent (or 
better) value for money, which would lead to a decrease in population health.  
Manufacturers of new interventions faced with this situation have two distinct options to 
consider (outside of revisiting the evidence and/or undergoing an appeal). One of these is to 
simply walk away, accept a negative recommendation by NICE and therefore forfeit the 
prospect of securing patient access via routine commissioning. The other is to propose a 
commercial arrangement between the NHS and the company to allow NICE to arrive at a 
positive recommendation – in other words, provide the intervention at a reduced price such 
that the ICER may fall below λ. 
A commercial arrangement (or patient access scheme [PAS]) will be proposed by a 
company for consideration by the Patient Access Scheme Liaison Unit (PASLU) at NICE. [1] 
The nature of the PAS may be public knowledge or confidential – the most common of which 
is a (confidential) simple percentage discount on the list price of the intervention. [2] The 
confidentiality of a simple PAS discount may provide an attractive option for companies 
seeking to procure patient access while also protecting the nature of any commercial 
agreements made in order to do so.  
Ultimately, the final decision made by NICE (i.e. a positive or negative recommendation 
issued by the Committee) is publicly available. Within the NICE guides to the methods and 
processes of technology appraisal, transparency is described as essential to ensure 
appropriate and robust decision making. [3,4] The guide to the methods of technology 
appraisal [3] states: 
The credibility of the guidance produced by the Institute is dependent on the transparency 
of the Appraisal Committee's decision-making process. It is crucial that the Appraisal 
Committee's decisions are explained clearly with reference to all the available evidence, 
and that the contributions of clinical specialists, commissioning experts, patient experts 
and the views of people who responded to consultation during the appraisal are 
considered. The reasoning for the Committee's decision will be explained, with reference 
to the factors that have been taken into account, in the 'Considerations' section of the 
guidance. 
Because many factors are taken into account when the Committee makes a decision, it is 
possible that some factors bring benefits that outweigh other barriers. While a λ of £20,000 
per QALY gained may have originally been set to maximise health (i.e. ensure that the 
benefits of a new technology outweigh the opportunity costs), NICE has been explicit in its 
tolerance of higher values of λ when other factors are evident. For instance, when 
considering ‘end-of-life’ therapies, NICE has been willing to issue positive recommendations 
when the ICER clearly exceeded the estimated opportunity cost (i.e. λ of £20,000 per QALY 
gained). [5] This reflects the ‘social value judgement’ that end-of-life treatment might be 
more valued than other care. In effect, it means that we (society) may be willing to accept a 
lower aggregated ‘population’ health, in order to see end-of-life given priority. The important 
point, though, is that we (society) should be able to fully understand the trade-offs that are 
being made on our behalf.  
If ICERs used to inform decision making (i.e. those including the confidential PAS discount) 
are withheld from the public due to commercial reasons, then the population is being asked 
to give up an unspecified amount of health. In such cases, it is impossible for this to be a 
truly informed social value judgement, at least from the perspective of those outside 
Committee membership. Therefore, while members of the public may not always agree with 
decisions made by NICE, it is important that the public is able to understand the rationale 
behind them. As such, there is a clear conflict of interests for NICE to make decisions 
transparently while also protecting the confidentiality of PAS discounts (and thus be able to 
recommend treatments which offer value for money). 
The objective of this study was to investigate how NICE has balanced these two ideals when 
providing evidence used to support its decision making. A review of all recommendations 
made by NICE that included a confidential, simple PAS discount was carried out to identify 
instances of reduced transparency (and thus decision making that appears ill-founded in 
relation to the presented evidence) as well as any documentation wherein confidential 
information may be back-calculated or estimated based on the evidence presented. By 
performing this study, the subtleties associated with balancing conflicting principles may be 




Guidance for technologies assessed by NICE are published on the NICE website 
(www.nice.org.uk), which includes guidance from the single technology appraisal (STA), 
multiple technology appraisal (MTA), and highly-specialised technology (HST) appraisal 
programmes (in addition to other types of guidance relating to medical devices, surgical 
procedures and diagnostic tools). While the majority of documents are publicly-available, 
parts of these are redacted owing to the incorporation of academically- or commercially-
sensitive information – the latter of which is typically due to the specification of a commercial 
arrangement (or PAS).  
In addition to the guidance issued for NICE-assessed technologies, a list of all medicines 
approved with a PAS is also available on the NICE website. [2] Approved technologies 
including a commercial arrangement were extracted from the NICE website, and categorised 
by type of commercial arrangement. The key types of commercial arrangement permitted by 
NICE are presented in Table 1. 
The primary focus of our study was to consider those technologies with an approved, 
confidential, simple PAS discount. Consequently, technologies with an approved complex 
PAS discount scheme or commercial access agreement were excluded. 
Technologies with an approved simple PAS may have been assessed via the STA, MTA or 
HST programmes though only STA guidance was considered within the study. MTA 
guidance was excluded as companies are not obligated to submit cost-effectiveness 
evidence within submissions. HST guidance was excluded due to differences in the 
decision-making process versus the STA or MTA programmes, and the small number of 
completed HST appraisals.   
After applying the aforementioned exclusion criteria, the total number completed STA 
appraisals with an approved simple PAS discount was identified. For these appraisals, the 
published Final Appraisal Determination (FAD) document was downloaded, which contained 
the evidence presented by NICE from which the final decision was made. The NICE website 
provides a range of documentation published throughout the time period over which a given 
technology is appraised, including company submissions, Evidence Review Group (ERG) 
reports etc. However, these interim documents reflect the Committee’s preferred 
assumptions and results at the time of publication, which may contradict those in the final 
published guidance. Consequently, only the cost-effectiveness results presented within the 
FAD may be considered to form the basis of the final decision made by NICE. 
Subsequently, we searched the FAD to identify the cost-effectiveness results (i.e. the ICER 
and/or its component parts) from which the final decision was made. Where a definitive 
ICER was presented, we searched the most recent interim documentation to ascertain the 
nature of redaction presented to protect commercially-sensitive information (e.g. the slides 
presented at the Committee meeting, or the most recent ERG report). For appraisals where 
the FAD did not contain a definitive ICER, company submission documentation (including 
results with the PAS discount) were searched to establish the nature of redaction presented. 
Redaction methods were categorised according to the following:  
• Unreported – the FAD does not contain any ICER, or its component parts  
• Range – the FAD states that the ICER was above, below or between a given value(s) 
• Reported – the FAD provides a single ICER from which the final decision was based 
Next, we investigated whether the conclusion reached by NICE appeared justified in light of 
the evidence presented in the FAD. The conclusion reached was deemed justified if the 
ICER(s) presented were less than or equal to the specified λ, or if NICE stated that while the 
ICER was greater than λ, the treatment was recommended on the basis of other social value 
judgements. The specification of a decision as “justified” or “unjustified” is purely made in 
relation to the presentation of the ICER, and not whether the decision was correct or 
incorrect. 
Academically-sensitive evidence may be provided by companies to aid Committee decision 
making. However, presentation of such within the public domain may prejudice future 
publication of the information in a scientific publication. [6] In public Committee meetings, 
these data are presented on the slides shown to the public, but are omitted from 
paper/online versions of the meeting slides and other documentation (e.g. the FAD). The 
agreement between the Association of the British Pharmaceutical Industry (ABPI) and NICE 
states that for unpublished clinical trial data, a minimum period of 12 months from publication 
of the clinical study report (CSR) is considered appropriate over which data are redacted. [6] 
While redaction of these data is of clear importance while awaiting publication, if these data 
are never revealed within NICE documentation (except for those in attendance of the public 
Committee meetings), the transparency of past decision making is compromised. With this in 
mind, we searched company submissions for instances of academic-in-confidence 
redaction. It was not possible to ascertain dates of CSR publication for each included trial, so 
the aforementioned minimum period of 12 months could not be directly applied. Instead, we 
report the number of STAs which include academic-in-confidence redaction which were 
published at least 12 months ahead of the extraction date – thus guaranteeing a minimum of 
12 months had elapsed, but more likely a minimum of 18 months (given the length of the 
NICE process). 
For those STAs including a simple PAS discount, we attempted to back-calculate the volume 
of discount based on the information presented within the public domain. STA 
documentation was searched to ascertain the methods used to redact commercially-
sensitive information. If this clearly prohibited estimation of the PAS (e.g. complete removal 
of all cost-effectiveness results), no further attempts were made at estimating the PAS. 
However, if enough information was available (e.g. disaggregated total costs), back-
calculation was attempted. In the interest of keeping PAS discounts confidential, we do not 
refer to specific STAs in our results. 
Given the confidential nature of the ‘true’ volume of discount, it was not possible to verify 
whether the estimated volume of PAS discount was correct. However, the method of 
estimation was verified by another reviewer to check the approach used was logically sound. 
In addition, it was not possible to adopt a fully-systematic approach to estimate the PAS 
associated with each product, due to differences in reporting, redaction, and estimation 
methods required. As such, the objective of this aspect of the study was to establish whether 
or not back-calculation of the PAS discount was possible for a non-zero number of STAs. 
 
3. Results 
A list of all published NICE technology appraisal guidance was downloaded from the NICE 
website on 26 October 2018. The identification of STAs relevant to this study is presented in 
the form of a Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) diagram (Figure 1). 
Prior to exclusion of appraisals, a total of 118 products were found have an approved 
commercial arrangement. The approved commercial arrangements were used to inform 171 
distinct STAs, MTAs and HST appraisals. From these, a total of 110 STAs with an approved 
simple PAS discount were identified, of which 62 (56.36%) were conducted in cancer. Of the 
remaining 48, the most common disease areas for which simple PAS discounts were used 
were in ophthalmology (n=10), dermatology (n=9), and rheumatology (n=8). A summary of 
the included STAs by disease area is provided in Figure 2. 
For each of the relevant STAs, the FAD was searched to ascertain the transparency of the 
recommendation issued. In 24 (21.8%) STAs, no ICER was presented within the FAD – this 
illustrates that a substantial proportion of recommendations made for products including a 
PAS discount lack the necessary transparency such that the decision made is well founded. 
In 66 (60.0%), an ICER range was presented (i.e. the ICER was above, below or between a 
given value[s]). While an improvement on presenting no ICER at all, statement of an ICER 
range precludes the understanding of the Committee-preferred assumptions or scenarios 
(and thus ultimate results) that factored into their decision making. In the remaining 20 STAs 
(18.2%), a final ICER was presented including the PAS from which the decision was made.  
For STAs which reported either an ICER or ICER range (n=86 STA, 78.2%), the decision 
was considered justified by the cost-effectiveness evidence presented (and any associated 
social value judgments). For these STAs, the company submission was searched to 
ascertain the methods used to redact commercially-sensitive information (i.e. the volume of 
discount). Most submissions redacted the component figures that contribute to the ICER (i.e. 
the incremental costs and QALYs). However, in a small number of cases, full results were 
presented including the PAS discounts, with results excluding the PAS discount fully 
redacted. Presentation of results in this manner offered the greatest transparency.  
It was noted that even between submissions by the same company, censoring methods may 
differ. Two examples of this are presented in Table 2. In the two submissions by Pfizer, one 
had all the component costs, QALYs and life years (LYs) were redacted; however, in the 
other submission, ICERs were presented. In the two submissions by Novartis, the ICERs 
including the PAS were presented; however, only in one of the submissions were the 
component QALYs and LYs were provided. These examples demonstrate excessive 
censoring, as LYs do not form a part of the ICER, yet are redacted. 
For those STAs where the decision did not appear justified (n=24, 21.8%), the date of FAD 
publication was used to establish whether there was a difference in the justification of the 
decision made over time. Of the 24 STAs considered to exhibit “unjustified” decisions, 21 
were published in the past 3 years.  
Nearly all the STAs published before 2018 (n=68 out of 86, 79.1%) included the redaction of 
some academically-sensitive information – usually data were redacted from the latest trial 
cut-off, or from the clinical study report (not in the public domain). As these data were 
redacted, it is not possible to determine whether they could also contribute to the protection 
of the commercially-sensitive discount. However, there were some clear instances where 
this appeared important (relating to the proportion of patients expected to remain on 
treatment over time)  
For the STAs including a simple PAS discount, back-calculation of the PAS discount was 
attempted. We were able to back-calculate the PAS discount in at least seven cases. In 
some cases, the methods used were relatively simple (e.g. comparing between tables to 
cross reference missing numbers). In other cases, the methods required partial rebuilding of 
a model. It is likely that a larger number of PAS discounts could have been estimated by 
essentially re-building the submitted cost-effectiveness models, however, this was beyond 
the scope of our study which was to look at easily back calculable discounts. 
 
4. Discussion 
The results of our review demonstrate that at present censoring appears to be performed on 
an ad hoc basis with no consistent pattern in the information censored. This applies not just 
between companies, but also between submissions from the same companies. The 
approach of censoring all (or at least the majority of) cost-effectiveness results leads to 
reduced transparency, with few decisions appearing justifiable in light of the information 
presented. However the ad hoc approach if implemented poorly does not even necessarily 
keep discounts confidential (our cursory analysis was able to estimate the PAS in a non-
trivial number of cases). 
Of particular concern was the number of appraisals where all outcome information is 
censored. This raises a number of issues and greatly undermines the legitimacy of the HTA 
process – in many instances even LYs (which are completely unrelated to PAS discounts) 
were censored. Based on the lack of information presented in cases such as these, a patient 
would not be able to understand the evidence presented regarding their likely outcome with 
treatment. Conversely, patients asked to forgo treatments would not be able to understand 
why a given technology is funded in preference to the one they would desire. In the latter 
case, we feel it is particularly important that patients may comprehend how trade-offs have 
been made relating to aggregated population health. Worryingly, the majority of ‘unjustified’ 
decisions identified by this review were published in the last 3 years, which we hope does 
not indicate a trend. 
A secondary finding was that the volume of data censored as academic-in-confidence is 
extremely high. Given the length of time since decisions were published (some as much as 
10 years ago), it is unlikely that the majority of academically-sensitive information remains as 
such – indeed most should be published within a year of CSR publication (and consequently, 
less than a year after NICE documents are published online). Despite this however, there 
exists no step (such as embargo for a year as seen with some academic publications), by 
which academic-in-confidence information is uncensored in the NICE process – this ideally 
would be rectified when the NICE methods guide is next updated (if not sooner). An example 
of such data can be seen in NICE TA552 which includes large quantities of redacted clinical 
data, including baseline patient characteristics from the pivotal clinical study. [7] The table of 
characteristics with partial-redaction (dated July 2018 in the NICE committee papers) was 
subsequently published (in full) in September 2018; while the FAD was published in 
November 2018. [8,9] Nevertheless, these data will remain redacted on the NICE website in 
perpetuity under current process. 
Our review has some limitations, in that we did not include MTAs, assessments where more 
than one treatment was subject to a PAS, or assessments where a complex PAS was 
applied. Whilst those excluded studies may have proven to be more difficult to back-
calculate the PAS from available information, it would not affect the issues raised around 
transparency in decision making. 
We also note that several of the findings of our review may be useful more broadly within 
HTA field – for example, how redaction may inadvertently reveal commercially-sensitive 
information if performed incorrectly. NICE highlight the importance of transparency within 
their methods guide, though this sentiment may not be considered as important for other 
markets in light of the role pricing negotiations may have on the decisions made. Ozierański 
et al., (2019) recently published a summary of the transparency of decisions made by the 
Polish Agency for Health Technology Assessment (AHTAPol). [10] The authors of this study 
found that of the 332 assessments they assessed, the relationship between costs, health 
effects and the threshold price was redacted in 290 (87.3%) of cases. However, unlike our 
findings, the proportion of AHTAPol assessments that were redacted appears to be 
decreasing on a per-year basis (100.0% of those conducted in 2012, versus 76.7% in 2015). 
5. Recommendations and conclusions 
Based on the results of our review, there are multiple ways in which redaction could be 
performed, none however (by definition) offers both perfect transparency and the ability to 
maintain the confidentiality of PAS discounts. We recommend a balanced approach be 
undertaken (where possible) by censoring ‘without PAS’ results, and not providing fully 
disaggregated costs for the ‘with PAS’ results such that the final ICER (including the PAS) 
may be reported in the public domain. This approach constitutes an improvement on many 
previous appraisals for which the decision was either completely opaque or for which the 
PAS may be inadvertently ‘back-calculated’. However, it is noted that this is may not be 
possible in cases where a PAS discount is introduced mid-way through the NICE process. 
Given the findings of our work we would suggest that the current approach to redaction 
needs refining, and potentially codifying. Firstly, some level of standardisation should be 
applied to commercially-sensitive discounts, to ensure that transparency is maintained as 
much as possible (with particular reference to specific approaches, per our suggestion 
above). Secondly, we believe the embargo period specified for academic-in-confidence data 
should be adhered to, in order to ensure information is released when no longer 
academically sensitive. A 12-month period following publication of final guidance on the 
NICE website over which information remains confidential would seem sufficient to ensure 
any material likely to be published, has been (this in reality would mean the data was first 
generated at least 2 years before being made publicly available, and more likely 3 years). 
Whilst it may not be possible (without total censoring) to allow a PAS to be completely 
hidden, transparency is vital for the validity of HTA as an institution, thus transparency in 
evidence submitted by companies should be encouraged where possible. Updated NICE 
guidance on this topic may improve overall transparency, and prevent the inadvertent 
disclosure of commercially-sensitive information.  
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